Diagnosed with cutaneous vasculitis, urticaria, psoriasis, acne, bullous skin diseases, sterile pustulosis, leprosy, pneumocystis pneumonia and any other patients who need dapsone administration.
Subjects are dapsone-naive.
All subjects must have a clinical need for treatment with dapsone that precedes the decision to participate in the study.
All subjects are willing to complete the 6-weeks period clinical trial.
All subjects are written informed consent.

NCT02550080_inc_T1
Condition
cutaneous vasculitis
NCT02550080_inc_T2
Condition
urticaria
NCT02550080_inc_T3
Condition
psoriasis
NCT02550080_inc_T4
Condition
acne
NCT02550080_inc_T5
Condition
bullous skin diseases
NCT02550080_inc_T6
Condition
sterile pustulosis
NCT02550080_inc_T7
Condition
leprosy
NCT02550080_inc_T8
Condition
pneumocystis pneumonia
NCT02550080_inc_T9
Drug
dapsone
NCT02550080_inc_T10
Drug
dapsone
NCT02550080_inc_T11
Negation
naive